Alzheimer i disease (AD) is the most common form of dementia in occidental countries. Currently approved treatments for AD provide mainly symptomatic benefits without clear evidence of neuroprotection. N-methyl-D-aspartate (NADA) receptor antagonists have therapeutic potential in several central nervous system disorders, including neuroprotective treatment in chronic neurodegenerative diseases, and symptomatic treatment in other neurologic diseases. Memantine, an NMDA antagonist, has been recently approvedfor the treatment of advanced AD. Due to its mechanism of action, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies. In addition, memantine is a useful symptomatic treatmentfor AD and vascular dementia. This paper reviews both aspects of memantine as well as some basic mechanisms mediating cognition and glutamatergic neurodegeneration.
1. Lobo A, Launer LJ, Fratiglioni L, et al.: Prevalence of dementia and major subtypes in Europe: A collaborative study of populationbased cohorts. Neurology Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl. 5): S4-S9.
2.
2. Launer LJ, Hofman A: Frequency and impact of neurologic diseases in the elderly of Europe: A collaborative study of populationbased cohorts. Neurology. 2000; 54(11 Suppl. 5): S1-S8.
3.
3. Hebert LE, Scherr PA, Bienias JL, et al.: Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol. 2003; 60: 119-1122.
4.
4. Schenk D, Barbour R, Dunn W, et al.: Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400: 173-177.
7. Jain KK: Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs. 2000; 9: 1397-1406.
8.
8. Winblad B, Mobius HJ, Stöler A: Glutamate receptors as a target for Alzheimer's disease-are clinical results supporting the hope?J Neural Transm Suppl. 2002; 62: 217-225.
9.
9. Danysz W, Parsons CQBresink I, et al.: Glutamate in CNS disorders: A revived target for drug development?Drug News Perspect. 1995; 8: 261-277.
10.
10. Muller WE, Mutschler E, Riederer P: Noncompetitive NMDA receptor antagonists with fast open channel kinetics and strong voltage dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry. 1995; 28: 113-124.
11.
11. Rothman SM, Olney JW: Excitotoxicity and the NMDA receptors. TrendsNeurosci. 1987; 10: 299-302.
12.
12. Kornhuber J, Quack G: Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett. 1995; 195: 137-139.
13.
13. Rammsayer TH: Effects of pharmacologically induced changes in NMDA-receptor activity on long term memory in humans. Learn Mem. 2001; 8: 20-25.
14.
14. Danysz W, Parsons CQMöius HQ et al.: Neuroprotection and symptomatological action of memantine relevant for Alzheimer's disease: A unified hypothesis on the mechanisms of action. Neurotox Res. 2000; 2: 85-98.
15.
15. Danysz W, Parsons CG: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: Preclinical evidence. Int J Geriatr Psychiatry. 2003; 18: S23-S32.
16.
16. Thompson RF, Kim JJ: Memory systems in the brain and localization of a memory. Proc NatlAcadSci USA. 1996; 93 (24): 13438-13444.
17.
17. Baudry M, Davis JL (eds.): Long-Term Potentiation: A Debate of Current Issues. Cambridge, MA: MIT Press, 1991.
18.
18. Lynch G. Baudry M: The biochemistry of memory: A new and specific hypothesis. Science. 1984; 224 (4653): 1057-1063.
19.
19. Landfield PW, Deadwyler SA (eds.): Long-Term Potentiation: A Debate of Current Issues. Cambridge, MA: MIT Press, 1988.
20.
20. Baudry M, Thompson RF, Davis JL (eds.): Synaptic Plasticity, Molecular, Cellular, and Functional Aspects. Cambridge, MA: MIT Press, 1993.
21.
21. Masliah E, Mallory M, Aldford M, et al.: Caspase dependent DNA fragmentation might be associated with excititoxicity in Alzheimer's disease. J Neuropathol Exp Neurol. 1998; 57: 1041-1052.
22.
22. Li S, Mallory M, Aldford M, et al.: Glutamate transporter alteration in Alzheimer's disease are possibly associated with abnormal APP expression. JNeuropathol Exp Neurol. 1997; 56: 901-911.
23.
23. Arias C, Arrieta I, Tapia R: Beta-amyloid peptide fragment 25-35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. JNeurosciRes. 1995; 41:561-566.
25. Couratier P, Sindou P, Tabarud E, et al.: Modulation of tau neuronal expression induced by NMDA, non-NMDA and metabotropic glutamate receptor agonists. Neurodegeneration. 1995; 4: 33-41.
26.
26. Sobolevsky A, Koshelev SGQKhorodov BI: Interaction of memantine and amantadine with agonist unbound NMDA receptor channels in acutely isolated rat hippocampal neurons. J Physiol. 1998; 512: 47-60.
27.
27. Parsons CG, Danysz W, Quack G: Memantine and the aminoalkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists in vitro characterization. Amino Acids. 2000; 19: 157-166.
28.
28. Berger W, Deckert J, Hartmann J, et al.: Memantine inhibits [3H]MK-801 binding to human hippocampal NMDA receptors. Neuroreport. 1994; 5(10): 1237-1240.
29.
29. Frankiewicz T, Parsons CG: Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg+2 in hippocampal slices. Neuropharmacology. 1999; 38: 1253-1259.
30.
30. Pellegrini JW, Lipton SA: Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol. 1993; 33: 403-407.
31.
31. Lahiri DK, Alley GM, Morgan C, et al.: Effects of memantine on levels of the amyloid beta peptide in cell cultures. Eur Neuropsychopharmacol. 2003; 13(Suppl 4): S391-S391.
32.
32. Iqbal K, Liang Li, Sengupta A, et al.: Memantine restores the okadaic acid induced changes in the activities of protein phosphatase-2A in rat hippocampal slices in culture. Eur Neuropsychopharmacol. 2003; 13(Suppl 4): S393-S394.
33.
33. Wenk GL, Zajaczkowski W, Danysz W: Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res. 1997; 83: 129-133.
34.
34. Miguel-Hidalgo JJ, Alvarez XA, Quack G: Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res. 2002; 958: 210-221.
35.
35. Barnes CA, Danysz W, Parsons CG: Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long term potentation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur JNeurosci. 1996; 8: 565-571.
37. Reisberg B, Doody R, SofflerA, et al.: Memantine in moderate to severe Alzheimer's disease. N Engl J Med. 2003; 348(14): 1333-1341.
38.
38. Orgogozo JM, Rigaud AS, Stoeffler A, et al.: Efficacy and safety of Memantine in patients with mild to moderate vascular dementia. Stroke. 2002; 33: 1834-1839.
39.
39. Gdertelmeyer R, Erbler H: Memantine in the treatment of mild to moderate dementia syndrome. Arzneimittelforschung. 1992; 42: 904-913.
40.
40. Pantev M, Ritter R, Goertelmeyer R: Clinical and behavioural evaluation in long term care patients with mild to moderate dementia under memantine treatment. Zeitschriftfiur Gentopsychologie undpsychiatrie. 1993; 6: 103-117.
41.
41. Winblad B, Poritis N: Memantine in severe dementia: Results of the M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999; 14: 135-146.
42.
42. Reisberg B, Mobius HJ, Schmidtt F, et al.: Long term efficacy and safety benefits from treatment with the NMDA antagonist memantine. Eur Neuropsychopharmacol. 2003; 13(Suppl 4): S388-S389.
43.
43. Möius HJ: Pharmacological rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord. 1999; 13(Suppl 3): S172-S178.
44.
44. Wilcock QMobius HJ, Stöfler A: A double blind, placebo controlled multicenter study of Memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002; 17(6): 297-305.
45.
45. Mobius HJ, Stofler A: Memantine in vascular dementia. Int Psychogeriatr. 2003; 15(S 1): 207-213.
46.
46. Periclou A, Ventura D, Sherman T, et al.: Pharmakokinetic study of memantine and donepezil in healthy young subjects. Eur Neuropsychopharmacol. 2003; 13(Suppl 4): S398-S398.
47.
47. Farlow MR, Tariot PN, Grossberg GT, et al.: Memantine/ donepezil dual therapy is superior to placebo/donepezil therapy for the treatment of moderate to severe Alzheimer's disease. Neurology. 2003; 60(S 1): A412-A412.
